{
  "erlotinib": {
    "targets": [
      "EGFR"
    ],
    "class": "EGFR Tyrosine Kinase Inhibitor",
    "generation": "1st",
    "fda_approved": true,
    "indications": [
      "Non-small cell lung cancer"
    ],
    "mechanism": "Reversibly inhibits EGFR tyrosine kinase",
    "biomarkers": [
      "EGFR mutations"
    ],
    "resistance_mutations": [],
    "response_rate": "70% (EGFR+ first-line)",
    "clinical_context": "standard approval pathway",
    "fda_verified": true,
    "nda_number": "021743",
    "approval_date": "2004-11-18",
    "special_designations": [],
    "companion_diagnostics": []
  },
  "osimertinib": {
    "targets": [
      "EGFR",
      "EGFR T790M"
    ],
    "class": "EGFR Tyrosine Kinase Inhibitor",
    "generation": "3rd",
    "fda_approved": true,
    "indications": [
      "EGFR-mutated NSCLC",
      "T790M resistance NSCLC"
    ],
    "mechanism": "Irreversibly inhibits EGFR and T790M mutant",
    "biomarkers": [
      "EGFR exon 19 deletion",
      "EGFR L858R",
      "EGFR T790M"
    ],
    "resistance_mutations": [],
    "response_rate": "70-80% (first-line EGFR+)",
    "clinical_context": "breakthrough therapy, multiple indications",
    "fda_verified": true,
    "nda_number": "208065",
    "approval_date": "2015-11-13",
    "special_designations": [
      "Breakthrough Therapy"
    ],
    "companion_diagnostics": []
  },
  "sotorasib": {
    "targets": [
      "KRAS G12C"
    ],
    "class": "KRAS Inhibitor",
    "generation": "1st",
    "fda_approved": true,
    "indications": [
      "KRAS G12C mutated locally advanced or metastatic NSCLC"
    ],
    "mechanism": "Covalently binds KRAS G12C in GDP-bound state",
    "biomarkers": [
      "KRAS G12C mutation"
    ],
    "resistance_mutations": [],
    "response_rate": "37% overall response rate",
    "clinical_context": "first-in-class, accelerated approval",
    "fda_verified": true,
    "nda_number": "214665",
    "approval_date": "2021-05-28",
    "special_designations": [
      "Accelerated Approval",
      "First-in-Class"
    ],
    "companion_diagnostics": []
  },
  "adagrasib": {
    "targets": [
      "KRAS G12C"
    ],
    "class": "KRAS Inhibitor",
    "generation": "1st",
    "fda_approved": true,
    "indications": [
      "KRAS G12C mutated locally advanced or metastatic NSCLC",
      "KRAS G12C mutated colorectal cancer"
    ],
    "mechanism": "Covalently binds KRAS G12C, locks in inactive state",
    "biomarkers": [
      "KRAS G12C mutation"
    ],
    "resistance_mutations": [],
    "response_rate": "43% (NSCLC), 22% (CRC)",
    "clinical_context": "accelerated approval, multiple indications",
    "fda_verified": true,
    "nda_number": "215400",
    "approval_date": "2022-12-12",
    "special_designations": [
      "Accelerated Approval"
    ],
    "companion_diagnostics": []
  },
  "olaparib": {
    "targets": [
      "BRCA1",
      "BRCA2",
      "HRD"
    ],
    "class": "PARP Inhibitor",
    "generation": "1st",
    "fda_approved": true,
    "indications": [
      "BRCA-mutated advanced ovarian cancer",
      "BRCA-mutated HER2-negative metastatic breast cancer",
      "BRCA-mutated metastatic pancreatic cancer",
      "BRCA-mutated metastatic castration-resistant prostate cancer"
    ],
    "mechanism": "Inhibits PARP1/2, exploits homologous recombination deficiency",
    "biomarkers": [
      "germline BRCA mutations",
      "HRD-positive"
    ],
    "resistance_mutations": [],
    "response_rate": "60% (BRCA+ ovarian)",
    "clinical_context": "first-in-class, multiple indications",
    "fda_verified": true,
    "nda_number": "206162",
    "approval_date": "2014-12-19",
    "special_designations": [
      "First-in-Class"
    ],
    "companion_diagnostics": [
      "BRACAnalysis CDx",
      "FoundationFocus CDxBRCA"
    ]
  },
  "talazoparib": {
    "targets": [
      "BRCA1",
      "BRCA2"
    ],
    "class": "PARP Inhibitor",
    "generation": "1st",
    "fda_approved": true,
    "indications": [
      "BRCA-mutated HER2-negative locally advanced or metastatic breast cancer"
    ],
    "mechanism": "PARP trapping, prevents DNA repair in BRCA-deficient cells",
    "biomarkers": [
      "germline BRCA1 mutations",
      "germline BRCA2 mutations"
    ],
    "resistance_mutations": [],
    "response_rate": "63% (BRCA+ breast)",
    "clinical_context": "standard approval pathway",
    "fda_verified": true,
    "nda_number": "211651",
    "approval_date": "2018-10-16",
    "special_designations": [],
    "companion_diagnostics": [
      "BRACAnalysis CDx"
    ]
  },
  "alpelisib": {
    "targets": [
      "PIK3CA"
    ],
    "class": "PI3K Inhibitor",
    "generation": "2nd",
    "fda_approved": true,
    "indications": [
      "PIK3CA-mutated, hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer"
    ],
    "mechanism": "Selectively inhibits PI3K\u03b1 isoform",
    "biomarkers": [
      "PIK3CA mutations"
    ],
    "resistance_mutations": [],
    "response_rate": "26% (PIK3CA+ breast)",
    "clinical_context": "standard approval pathway",
    "fda_verified": true,
    "nda_number": "212526",
    "approval_date": "2019-05-24",
    "special_designations": [],
    "companion_diagnostics": [
      "therascreen PIK3CA RGQ PCR Kit"
    ]
  },
  "vemurafenib": {
    "targets": [
      "BRAF V600E"
    ],
    "class": "BRAF Inhibitor",
    "generation": "1st",
    "fda_approved": true,
    "indications": [
      "BRAF V600E mutation-positive unresectable or metastatic melanoma"
    ],
    "mechanism": "Inhibits mutant BRAF V600E kinase activity",
    "biomarkers": [
      "BRAF V600E mutation"
    ],
    "resistance_mutations": [],
    "response_rate": "48% (BRAF+ melanoma)",
    "clinical_context": "standard approval pathway",
    "fda_verified": true,
    "nda_number": "202429",
    "approval_date": "2011-08-17",
    "special_designations": [],
    "companion_diagnostics": [
      "cobas 4800 BRAF V600 Mutation Test"
    ]
  },
  "dabrafenib": {
    "targets": [
      "BRAF V600E",
      "BRAF V600K"
    ],
    "class": "BRAF Inhibitor",
    "generation": "2nd",
    "fda_approved": true,
    "indications": [
      "BRAF V600E mutation-positive unresectable or metastatic melanoma",
      "BRAF V600E mutation-positive metastatic NSCLC",
      "BRAF V600E mutation-positive anaplastic thyroid cancer"
    ],
    "mechanism": "Selective BRAF kinase inhibitor",
    "biomarkers": [
      "BRAF V600E mutation",
      "BRAF V600K mutation"
    ],
    "resistance_mutations": [],
    "response_rate": "50% (BRAF+ melanoma)",
    "clinical_context": "multiple indications",
    "fda_verified": true,
    "nda_number": "202806",
    "approval_date": "2013-05-29",
    "special_designations": [],
    "companion_diagnostics": []
  },
  "crizotinib": {
    "targets": [
      "ALK",
      "ROS1",
      "MET"
    ],
    "class": "ALK Inhibitor",
    "generation": "1st",
    "fda_approved": true,
    "indications": [
      "ALK-positive metastatic NSCLC",
      "ROS1-positive metastatic NSCLC"
    ],
    "mechanism": "Multi-kinase inhibitor targeting ALK, ROS1, MET",
    "biomarkers": [
      "ALK rearrangements",
      "ROS1 rearrangements"
    ],
    "resistance_mutations": [],
    "response_rate": "65% (ALK+), 80% (ROS1+)",
    "clinical_context": "multiple indications",
    "fda_verified": true,
    "nda_number": "202570",
    "approval_date": "2011-08-26",
    "special_designations": [],
    "companion_diagnostics": [
      "Vysis ALK Break Apart FISH Probe Kit",
      "VENTANA ALK (D5F3) CDx Assay"
    ]
  }
}